#FHAwarenessDay is 1 day away! This #JCLSpotlight for #CholesterolMonth explores how a structured transition model can help bridge the gap for young FH patients moving from pediatric to adult care. #KnowFH 🔗 https://ow.ly/AHgs50ZQCsC

2 days until #FHAwarenessDay! Our #JCLSpotlight for #CholesterolMonth highlights how correcting LDL-C for Lp(a) improves FH diagnosis and reduces false positives. #KnowFH Read more: https://ow.ly/zAN150ZQ9XA

#JCLSpotlight for #CholesterolMonth: Are lipid-lowering drugs safe during pregnancy? This Czech nationwide study offers new insight into maternal and fetal outcomes. Read more: https://ow.ly/bp4P50ZNRqo

#JCLSpotlight for #CholesterolMonth: New research finds Lp(a) plasma levels have no major effect on coagulation phenotype, though high levels were associated with a mild increase in FV:C. 🔗 https://ow.ly/e7Eg50ZNsZR

Happy #CholesterolMonth! All month, we'll be highlighting the latest cholesterol-related research published in the JCL. First up in the #JCLSpotlight, from the Aug Edition: "Recurrence of CV events despite achieving LDL-C <1.4 mmol/L in patients w/ CAD": https://ow.ly/WP7t50ZHK29

JCL Roundtable: Lipid metabolism, brain health, and dementia prevention. Recorded at #NLAFall in Scottsdale, Drs. Saeed, Trippi, Palta, Niotis, and Maki dig into this critical topic. Have you read it yet? https://www.lipidjournal.com/article/S1933-2874(26)00142-X/abstract

#JCLSpotlight: Plasma-based low-grade inflammation & endothelial dysfunction explain a small but significant proportion of the association between n-3 polyunsaturated fatty acids and CV diseases. Read more: https://ow.ly/zeOq50ZA1V7

The July issue of the JCL is here! Our first #JCLSpotlight: "Unmet needs for lipid management in patients with peripheral arterial disease." Closing the LLT gap could mean better CV outcomes & quality of life for PAD patients. Read more: https://ow.ly/6gPn50Zz5q1

Upon learning of the JCL's recent Impact Factor increase, we received a thoughtful note from W. Virgil Brown, MD, MNLA, the journal's very first Editor. Few acknowledgments carry more weight than one from the person who built the foundation of our society's journal.

#JCLSpotlight: Over 2 years, treatment with pitavastatin calcium of CDO for adolescents resulted in no changes in vascular measures. Statin therapy safely lowered atherogenic lipid particles, potentially reducing cardiovascular risk. 🔗 https://ow.ly/QPYp50Znv6J

#JCLSpotlight: Depot-specific metabolic differences are evident in pediatric obesity. vWAT in children with OW/OB shows heightened lipotoxicity & mitochondrial stress, while sWAT exhibits fewer, less pronounced metabolic differences. 🔗 https://ow.ly/wX6F50Znv5P

#JCLSpotlight: Elevated first-trimester RC is independently associated with increased GDM risk — partially mediated by pre-pregnancy BMI and insulin resistance. Measuring RC early in pregnancy may improve GDM risk identification. 🔗 https://ow.ly/ixqC50Znv07

#JCLSpotlight: FCS clinical diagnosis scoring systems — including the North American system at threshold 45 — discriminate multifactorial PC from biallelic FCS & may improve equitable access to precision medicine for PC patients. 🔗 https://ow.ly/vlMk50Zjni2

#JCLSpotlight: In this 10-year study, lipid apheresis was associated with higher odds of ICU admission in patients with HTG-AP. Among LA-treated patients, baseline TG >56.5 mmol/L predicted prolonged hospitalization. 🔗 https://ow.ly/H1YR50Zjnf0

#JCLSpotlight: In this cohort study, patients with sHTG & eHTG had significantly higher incidence of AP & CV events vs normal TG, with risk increasing stepwise by TG level, especially for AP. 🔗 https://ow.ly/mer250ZjnaB

The June edition of the JCL is live — have you looked yet? First in the #JCLSpotlight: Could pretreatment LDL-C calculation at trial enrollment identify undiagnosed SH and enable opportunistic FH screening? 🔗 Read more: https://ow.ly/gYNN50ZiR4c

#JCLSpotlight: SGLT2i use in diabetic CAD patients was associated with modest LDL-C reductions and lower mortality/MACE risk, supporting further evaluation of their lipid-modifying role in secondary prevention. 🔗 https://ow.ly/OcLV50Z6kBY

#JCLSpotlight: Baseline apoB may drive long-term MACE recurrence in very young ACS survivors, highlighting its potential utility for risk stratification beyond traditional lipid markers. 🔗 https://ow.ly/VI1T50Z5BiG

#JCLSpotlight: LPL DNA methylation in adipose tissue differed in patients with PC compared with others, highlighting that different factors might contribute to PC and its associated risks. 🔗 https://ow.ly/ERfB50Z4HM6

#JCLSpotlight: Two-year pemafibrate treatment significantly improved liver stiffness & hepatic parameters in patients with MASLD, independent of weight loss or fat reduction, suggesting direct antifibrotic mechanisms. 🔗 https://ow.ly/sjVb50Z3nxF

#JCLSpotlight: Elevated RC baseline levels, variability & cumulative exposure are independently associated with increased stroke risk in patients with AF, underscoring the need for lipid-lowering strategies targeting RC. 🔗 https://ow.ly/Ghvh50Z2LZ6

The May edition of the Journal of Clinical Lipidology is LIVE & we're starting strong. #JCLSpotlight: Initiating triple LLT at ACS hospitalization may markedly reduce CV events through earlier and more complete LDL-C target achievement. 🔗https://ow.ly/4hxW50Z0nEt

#JCLSpotlight: Evinacumab achieved up to 82% LDL-C reduction in 2 autosomal recessive hypercholesterolemia cases — both without functional LDL receptors — highlighting the importance of early, intensive therapy. 📄https://ow.ly/gJ9h50YYs8b

#JCLSpotlight: A rare case of Niemann–Pick disease type B with sea-blue histiocytosis presenting as decompensated cirrhosis — where histopathology provided key diagnostic evidence when enzyme and genetic tests were unavailable. 📄 https://ow.ly/Rtxl50YW1CH

The 2026 ACC/AHA/Multisociety Dyslipidemia Guideline joins the growing international consensus: Lp(a) should be tested at least once in all adults. Drs. Michael J. Wilkinson and Marlys L. Koschinsky discuss the implications in the JCL 👉 https://ow.ly/5WKF50YVKjB

#JCLSpotlight: Repeat Lp(a) testing is generally unnecessary but could be considered in those near risk thresholds or those being evaluated for Lp(a)-lowering therapies. Read more: https://ow.ly/wZ8T50YV3Jk

HoFH is the most severe and difficult-to-treat form of FH. On #HoFHAwarenessDay, we invite you to read National Lipid Association's expert clinical consensus on FH in the JCL, including updated guidance on HoFH treatment and management. 🔗https://ow.ly/4ZMu50YTgCk

#JCLSpotlight: Higher serum AIM levels were associated with altered lipid metabolites and predicted incident dyslipidemia, with the strongest link to elevated LDL-C seen in women. Read more: https://ow.ly/UUXQ50YSqoC

#JCLSpotlight: PCSK9 inhibition reduces LpPLA₂ and IP-10 without altering the global inflammatory response or HDL antioxidant function, suggesting a decrease in chronic vascular inflammation without broad systemic immune effects. 📄 https://ow.ly/HuOe50YRPsB

#JCLSpotlight: PAD carries high cardiovascular risk, yet many patients still don't receive guideline-recommended lipid-lowering therapy. A new narrative review explores the unmet needs and health inequities driving this gap. 📄https://ow.ly/P6kP50YR655